Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409682 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT00409682 is a Phase 3 study of Crohn's Disease that has completed, run by Abbott. The registered enrollment target is 192 participants, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00409682, a Phase 3 study of Crohn's Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Conditions Studied
Interventions
- BIOLOGICAL Adalimumab
Study Locations (20)
California
- Site Reference ID/Investigator# 10287 - Los Angeles
- Site Reference ID/Investigator# 5223 - Orange
- Site Reference ID/Investigator# 4984 - San Francisco
New York
- Site Reference ID/Investigator# 8801 - Buffalo
- Site Reference ID/Investigator# 3734 - Mineola
- Site Reference ID/Investigator# 4913 - New Hyde Park
Florida
- Site Reference ID/Investigator# 4911 - Orlando
- Site Reference ID/Investigator# 7640 - Orlando
Illinois
- Site Reference ID/Investigator# 4316 - Chicago
- Site Reference ID/Investigator# 5901 - Maywood
Minnesota
- Site Reference ID/Investigator# 5102 - Rochester
- Site Reference ID/Investigator# 4285 - Saint Paul
Colorado
- Site Reference ID/Investigator# 5222 - Aurora
Connecticut
- Site Reference ID/Investigator# 5676 - Hartford
Georgia
- Site Reference ID/Investigator# 5904 - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409682
The ClinicalTrials.gov registry entry for NCT00409682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,413-participant average among 104 other Crohn's Disease trials with a reported enrollment target (92% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00409682 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT00409682 about?
NCT00409682 is a clinical study titled "Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease". The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
What is the current status of trial NCT00409682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2007-04. Estimated completion is 2010-05.
What conditions does trial NCT00409682 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00409682?
The interventions under investigation include: Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00409682?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00409682 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.